Richard J. Bellin
The University of Texas MD Anderson Cancer Center(US)AbbVie (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Acute Myeloid Leukemia Research, HIV/AIDS drug development and treatment, Peptidase Inhibition and Analysis
Most-Cited Works
- → Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer(2020)393 cited
- → Statins enhance efficacy of venetoclax in blood cancers(2018)84 cited
- → Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors(2017)66 cited
- → Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia(2021)33 cited
- → Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia(2018)6 cited
- → Do Statins Enhance the Anti-Cancer Activity of Venetoclax?(2017)1 cited
- → Figure S5 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia(2023)
- → Table S1 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia(2023)
- → Figure S2 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia(2023)
- → Figure S4 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia(2023)